Skip to content

Observation of effective dosage of ciprofol and propofol for the induction of deep sedation in fiberoptic bronchoscopy

Observation of effective dosage of ciprofol and propofol for the induction of deep sedation in fiberoptic bronchoscopy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062383
Enrollment
Unknown
Registered
2022-08-03
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthetic effect during painless bronchoscopy

Interventions

Sponsors

Mindong Hospital Affiliated to Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Plan to undergo elective electronic fiber bronchoscopy under general anesthesia; 2. 18<=age<=65, ASA?-?, 18<=BMI<=30 kg/m2; 3. No hearing, visual or intellectual impairment, and no other conditions that make it difficult to assess the degree of postoperative recovery.understand the basic principles of the experiment and signe an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Suffering from mental and neurological diseases (schizophrenia, Alzheimer's disease, epilepsia,etc.); 2. Electrolyte metabolism disorder before surgery, such as K+ = 5.5mmol/L; 3. Severe liver dysfunction, defined as ALT, AST, GGT and other related indicators >= 1.5 times normal value; 4. Severe renal inadequacy; 5. Serious cardiovascular and cerebrovascular diseases, such as unstable angina pectoris or myocardial infarction in the past six months, past severe angina pectoris, congestive heart failure, high-risk coronary artery disease, etc 6. Cannot breathe through the nose for various reasons; 7. Mallampati grade >=3 or combined with OSAHS; 8. Nasopharyngeal airway is contraindicated; 9. Patients with anticipated difficult airway, severe respiratory disease, acute respiratory tract infection, uncontrolled asthma and unexplained dyspnea; 10.Non-invasive arterial blood pressure monitoring is contraindicated; 11.Long term of alcoholism ,drug taking or drug abuse; 12.Allergic to active ingredients or related excipients of drugs used in the study; 13.Participated in other clinical trials within the last 3 months; 14.Other conditions that are not suitable for this clinical trial as judged by the investigator.

Design outcomes

Primary

MeasureTime frame
median effective dose;

Secondary

MeasureTime frame
MOAA/S score;blood pressure;heart rate;incidence of hypoventilation;cough score;intraoperative drug consumption;ncidence of adverse events;satisfaction;induction time;pain injection;

Countries

China

Contacts

Public ContactHuang Qingqing
494325099@qq.com+86 13599198422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026